In 2000, there were 600 million people aged 60 years and over; however, it has been
estimated that by 2050 this number will have increased to two billion people [9]. The world's …

New guideline recommendations prefer direct oral anticoagulants (DOACs) over warfarin in
DOAC-eligible patients with atrial fibrillation and patients with venous thromboembolism. As …

Many physicians are reluctant to prescribe oral anticoagulation therapy (OAT) because of
the fear of haemorrhagic complications. Changes in patient health, lifestyle or diet and other …

â••Unreal worldâ•• or â••real worldâ•• data in oral anticoagulant treatment of atrial fibrillation
Page 1 © Schattauer 2016 Thrombosis and Haemostasis 116.4/2016 587 Invited Editorial Focus …

The complexities of oral anticoagulation with warfarin have led to the search for more
practical alternative agents. Novel direct factor IIa inhibitors and direct factor Xa inhibitors …

Venous thromboembolism (VTE) is a highly morbid condition with several available oral
anticoagulant treatment options. Numerous studies have been published comparing …

Although warfarin has been the “king” of oral anticoagulation for the past few decades, its
reign is now jeopardized by the recent marketing in Canada of 3 new oral anticoagulants …

In patients with venous thromboembolism (VTE), the influence on outcome of using direct
oral anticoagulants (DOACs) at non-recommended doses or regimens (once vs twice daily) …

Concurrent antiplatelet therapy (APT) is common during warfarin therapy but is less well-
documented during direct oral anticoagulant (DOAC) therapy. Combined anticoagulant and …

Background Direct oral anticoagulants (DOACs) have emerged as promising alternatives to
vitamin K antagonists (VKAs) for patients with non-valvular atrial fibrillation (NVAF) or …